Rheumatoid arthritis has always been treated as a joint disease first and everything else second. A new mouse study published in the Journal of Pharmacology and Experimental Therapeutics complicates that framing: blocking a single inflammatory alarm protein, interleukin-33, quieted disease activity in the joints, the bloodstream, and the lungs at the same time.
The researchers combined two well established disease models, collagen-induced arthritis and inhaled bacterial endotoxin exposure, to recreate a scenario closer to real life: a body fighting joint inflammation while also breathing in airborne irritants. When they blocked interleukin-33, all three inflammatory fronts eased together.
An Alarm Protein With Reach Beyond the Airway
Interleukin-33, or IL-33, belongs to a small family of cytokines known as alarmins. Cells release it when they are damaged, stressed, or under attack, and it behaves less like a hormone and more like a fire alarm: fast, nonspecific, and capable of switching on multiple types of immune cells at once.
IL-33 signals through a receptor called ST2, found on mast cells, eosinophils, group 2 innate lymphoid cells, and certain T cells. That receptor profile is why IL-33 first drew attention in asthma and allergic airway disease, where it helps trigger the bronchoconstriction and mucus production behind flares.
More recently, the same alarm signal has turned up in autoimmune joint disease. Elevated IL-33 has been detected in the synovial fluid of people with rheumatoid arthritis, and animal studies have linked it to worsened joint swelling and cartilage breakdown.
Mast cells and group 2 innate lymphoid cells, the same responders IL-33 activates in the airway, are present in inflamed joint tissue as well. Once triggered, they release additional inflammatory chemicals that recruit more immune cells to the area, a feedback loop that can keep swelling going long after the original trigger has passed.
Building a Model Closer to Real Disease
Collagen-induced arthritis is the standard laboratory method for studying rheumatoid arthritis. Researchers immunize mice with a form of type II collagen, the protein found in cartilage, which trains the immune system to attack the animal’s own joints and produces swelling, cartilage damage, and bone erosion that closely mirror human disease.
For this study, the researchers layered a second stressor on top: repeated exposure to inhaled bacterial endotoxin, a component of the outer membrane of gram-negative bacteria commonly found in dust, mold, and polluted air. People living with autoimmune disease do not experience joint symptoms in isolation from what they breathe, and this combined model was built to reflect that.
With both stressors active, the mice developed inflammation in three separate compartments: swollen and damaged joints, elevated inflammatory markers circulating in the blood, and inflamed lung tissue. When the researchers blocked IL-33 signaling, markers of inflammation dropped across all three, not just the compartment closest to the original trigger.
Why One Signal Can Move Three Different Organs
The finding matters because joint disease and lung disease are usually managed as unrelated problems handled by different specialists. Rheumatoid arthritis falls to rheumatology, airway inflammation to pulmonology, and the two rarely intersect in a single treatment plan.
Joints and airways might seem unrelated, but both rely on barrier tissue, the synovium lining a joint and the epithelium lining the airway, that reacts to damage by releasing alarmins like IL-33 in the same way. A stimulus in one barrier tissue can activate immune cells that then travel to and act on the other.
Rheumatoid arthritis carries a well documented risk of lung involvement, including interstitial lung disease, and environmental exposures are already recognized as disease triggers. Cigarette smoke remains the strongest known environmental risk factor for developing rheumatoid arthritis, and population studies have linked occupational dust and silica exposure to higher disease risk in genetically susceptible people.
IL-33 offers a biological explanation for why an airway exposure might ripple outward into joint symptoms. Because IL-33 is released by damaged epithelial tissue anywhere in the body and signals through immune cells that circulate systemically, an alarm sounded in the lungs does not necessarily stay contained there.
The Drugs Already Exist, Just Not for This
IL-33 and its receptor are not new drug targets. Several antibody therapies designed to block the IL-33/ST2 pathway, including tozorakimab, itepekimab, and astegolimab, are already in clinical trials for chronic obstructive pulmonary disease and severe asthma.
None of them are approved or being tested specifically for rheumatoid arthritis in humans. This study is preclinical, conducted in mice, and its findings have not yet been replicated in people with joint disease.
What it does is strengthen the case for testing whether a drug class built for lung disease could have a second use in autoimmune joint disease, particularly in patients whose arthritis flares seem to track with respiratory irritation or infection.
What the Study Can’t Tell Us Yet
Mouse models of arthritis are useful because they are consistent and easy to measure, but they are not a perfect stand-in for the years-long, relapsing course of human rheumatoid arthritis. The mice in this study were exposed to endotoxin and immunized with collagen on a fixed, compressed timeline that does not fully capture how a person accumulates airway and joint exposures over decades.
It is also worth noting that blocking IL-33 removes an alarm signal the body evolved for a reason, helping clear damaged tissue and respond to certain infections and parasites. Long-term suppression of that pathway in humans would need careful study to rule out unintended effects on infection defense, something the current study was not designed to test.
What This Means If You Have Joint Pain
This study does not change how rheumatoid arthritis or joint pain is treated today, and interleukin-33 blockers are not available outside of clinical trials for lung disease. But the underlying message is worth paying attention to: joint inflammation is not necessarily sealed off from what happens in the airway.
For people managing autoimmune joint disease, limiting exposure to smoke, heavy dust, and air pollution is already standard advice for lung health. This research suggests those same exposures may be doing more to the joints than previously assumed, even if the mechanism has so far only been demonstrated in mice.
People who notice their joint symptoms tend to worsen after smoke exposure, seasonal air pollution spikes, or time spent in dusty environments may want to flag that pattern to a rheumatologist. It will not change a prescription today, but it adds useful detail to a disease that often defies simple triggers.
The immune system was never built along the lines of medical specialties. If a single alarm protein can move disease activity through the joints, the bloodstream, and the lungs in one motion, the line separating rheumatology from pulmonology may be more a matter of convenience than biology.
